{"organizations": [], "uuid": "ec7c9538ebc5b3127f3206c8b2c0b6f3fbf34113", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.wsj.com", "main_image": "http://si.wsj.net/public/resources/images/BN-KU484_1016va_G_20151016170045.jpg", "site_section": "http://www.wsj.com/news/markets", "section_title": "Stock Market &amp; Finance News - Wall Street Journal", "url": "http://www.wsj.com/articles/valeant-bears-get-some-satisfaction-1445037514", "country": "", "title": "Valeant Bears Get Some Satisfaction", "performance_score": 0, "site": "wsj.com", "participants_count": 1, "title_full": "Valeant Bears Get Some Satisfaction - WSJ", "spam_score": 0.0, "site_type": "news", "published": "2015-10-17T03:18:00.000+03:00", "replies_count": 0, "uuid": "ec7c9538ebc5b3127f3206c8b2c0b6f3fbf34113"}, "author": "Maureen Farrell", "url": "http://www.wsj.com/articles/valeant-bears-get-some-satisfaction-1445037514", "ord_in_thread": 0, "title": "Valeant Bears Get Some Satisfaction", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Bears on Valeant Pharmaceuticals International Inc. are getting their day —finally.\nThe drug company’s stock has been one of the best-performing this decade, and one of the most controversial.\nAt their peak closing price of $262.52 in early August,... To Read the Full Story, Subscribe or Sign In", "external_links": [], "published": "2015-10-17T03:18:00.000+03:00", "crawled": "2015-10-17T02:36:45.907+03:00", "highlightTitle": ""}